Machine Learning: The Next Frontier in Pharma Intelligence
Practical guide to help pharma execs determine when and how to use machine learning to drive business decisions.
Antibody-drug Conjugates: Takeaways and Best Practices for Strategy Planning
Antibody-drug conjugates have delivered meaningful improvements in outcomes for select patients over recent years, providing cancer patients with fewer and less severe side effects than traditional...
Hormonal Agents in Prostate and Breast Cancer: Takeaways and Best Practices for Strategy Planning
Hormonal therapy is a cornerstone of drug treatment for prostate cancer across all drug-treated populations (hormone-sensitive and castrate resistant settings) and is also widely used as a treatment...
Top 8 drug pricing disruptors going into 2019
Pitfalls and opportunities in the commercial healthcare market. As the managed care market pursues vertical integration and diversification, DRG sees disruptive change ahead for the U.S. healthcare...
PARP Inhibitors: Takeaways and Best Practices for Strategy Planning
The inhibition of PARP has emerged as a therapeutic approach in tumors that are intrinsically deficient in DNA repair, such as_BRCA1/2-mutation-positive breast or ovarian cancers. Particularly in...
ON THE ROAD TO MACRA: The Transition is Over, MACRA is Here to Stay
After several years of transition, the Medicare Access and CHIP Reauthorization Act of 2015 begins full implementation in 2019. Overall, the first round of the Merit-based Incentive Payment System...
RNA-based Therapies: Takeaways and Best Practices for Strategy Planning
Although no RNA (ribonucleic acid)-based therapeutic has yet been approved for an oncology indication, the nature of these agents means that this class encompasses a wide-range of agents and mechanism...
Checkpoint Inhibitors: Takeaways and Best Practices for Strategic Planning
Immune checkpoint inhibitors have revolutionized the field of oncology, providing an effective treatment option for several oncology indications. To date, seven immune checkpoint inhibitors have...
Biosimilars Insights Infographic
Global Biosimilars Pathways and Clinical Development Activity Since the introduction of the first biosimilar guidelines in 2005, the biosimilars field has continued to evolve. Almost 30 biosimilar...
CAR T-cell Therapies: Takeaways and Best Practices for Strategy Planning
Chimeric antigen receptor (CAR) T-cell therapies are the newest drug class in the continued development of personalized oncology treatments. The introduction of CAR T-cell therapy to aggressive...
A global consultancy and training agency providing market leading product & portfolio strategy, health economic outcomes research & evidence generation, value communication and training services across the life science industry.
We partner with both the biopharmaceutical and medical technology industry to support commercialization & patient access across a variety of functions including: R&D, commercial strategy, HEOR, market access, new product planning, marketing, data insights & analytics, business development and channel & segment customer engagement.
